MCM
ALXN

Manchester Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Manchester Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4
Closed -$1K – 826
2020
Q4 		$1K Buy
+4
New +$514 ﹤0.01% 719
2015
Q1 		– Sell
-169
Closed -$31K – 958
2014
Q4 		$31K Hold
169
– – ﹤0.01% 822
2014
Q3 		$28K Hold
169
– – ﹤0.01% 837
2014
Q2 		$26K Hold
169
– – ﹤0.01% 830
2014
Q1 		$26K Buy
+169
New +$26.9K ﹤0.01% 735
2013
Q4 		– Sell
-169
Closed -$20K – 974
2013
Q3 		$20K Hold
169
– – ﹤0.01% 744
2013
Q2 		$16K Buy
+169
New +$16.3K ﹤0.01% 783

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $7.94B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $14.1B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $4.65B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return